Moleculern™ – The Next Evolution in Drug Discovery Screening each Moleculern™ fragment against a curated protein target library has resulted in 600K real/empirical data points and scaffold-like compounds that can be used to design new drug candidates and to accelerate the discovery process. Our empirically rich Moleculern™ technology is rapidly creating, discovering, and developing novel pre-clinical to clinical stage agents. Our modern chemical biology approach coupled with our advanced machine learning and AI-backed platform accelerates discoveries by mapping hot-spots, computing ligand properties and building accurate empirical models which translate into active, safe, and efficacious novel chemical entities (NCEs) of future medicines.